These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32071911)

  • 21. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.
    Kudo M; Finn RS; Cheng AL; Zhu AX; Ducreux M; Galle PR; Sakamoto N; Kato N; Nakano M; Jia J; Vogel A
    Liver Cancer; 2023 Oct; 12(5):479-493. PubMed ID: 37901766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis.
    Kaneko S; Tsuchiya K; Yasui Y; Inada K; Kirino S; Yamashita K; Osawa L; Hayakawa Y; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Takeguchi T; Takeguchi Y; Nagano T; Nakanishi H; Itakura J; Takahashi Y; Himeno Y; Hoshi A; Kurosaki M; Izumi N
    Hepatol Res; 2020 Dec; 50(12):1375-1385. PubMed ID: 32924266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
    Fuchigami A; Imai Y; Uchida Y; Uchiya H; Fujii Y; Nakazawa M; Ando S; Sugawara K; Nakayama N; Tomiya T; Mochida S
    PLoS One; 2020; 15(4):e0231427. PubMed ID: 32275701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
    Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
    Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
    Kudo M; Galle PR; Brandi G; Kang YK; Yen CJ; Finn RS; Llovet JM; Assenat E; Merle P; Chan SL; Palmer DH; Ikeda M; Yamashita T; Vogel A; Huang YH; Abada PB; Yoshikawa R; Shinozaki K; Wang C; Widau RC; Zhu AX
    JHEP Rep; 2021 Apr; 3(2):100215. PubMed ID: 33392490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Koizumi A; Komatsu S; Omiya S; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; So S; Yoshida T; Arai K; Fujinaka R; Shimura Y; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2024 May; 44(5):2055-2061. PubMed ID: 38677746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.
    Hiraoka A; Kumada T; Tada T; Ogawa C; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
    Gastroenterol Rep (Oxf); 2021 Apr; 9(2):133-138. PubMed ID: 34026220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A multicenter study.
    Zhang Y; Numata K; Imajo K; Uojima H; Funaoka A; Komiyama S; Ogushi K; Chuma M; Irie K; Kokubu S; Yoneda M; Kobayashi T; Hidaka H; Fukushima T; Kobayashi S; Morimoto M; Kagawa T; Hattori N; Watanabe T; Iwase S; Maeda S
    Hepatol Res; 2024 Dec; 54(12):1174-1192. PubMed ID: 38953838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kaibori M; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kosaka H; Hiasa Y; Kudo M
    Liver Cancer; 2023 Aug; 12(3):209-217. PubMed ID: 37601983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
    Tomonari T; Sato Y; Tani J; Hirose A; Ogawa C; Morishita A; Tanaka H; Tanaka T; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Uchida K; Masaki T; Takayama T
    Hepatol Res; 2021 Apr; 51(4):472-481. PubMed ID: 33238074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
    Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
    Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
    Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Shibata H; Aoki T; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kudo M; Kumada T; ;
    Oncology; 2023; 101(9):542-552. PubMed ID: 37552968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment.
    Hu K; Yuan J; Tang B; Zhang F; Lu S; Chen R; Zhang L; Ren Z; Yin X
    Ann Transl Med; 2021 Feb; 9(3):237. PubMed ID: 33708864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
    Tomonari T; Tani J; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Kawano Y; Morishita A; Okamoto K; Sogabe M; Miyamoto H; Masaki T; Takayama T
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.
    Hiraoka A; Michitaka K; Kumada T; Izumi N; Kadoya M; Kokudo N; Kubo S; Matsuyama Y; Nakashima O; Sakamoto M; Takayama T; Kokudo T; Kashiwabara K; Kudo M
    Liver Cancer; 2017 Nov; 6(4):325-336. PubMed ID: 29234636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment.
    Hatanaka T; Kakizaki S; Nagashima T; Namikawa M; Ueno T; Tojima H; Takizawa D; Naganuma A; Arai H; Sato K; Harimoto N; Shirabe K; Uraoka T
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
    Sekiguchi S; Tsuchiya K; Yasui Y; Inada K; Kirino S; Yamashita K; Hayakawa Y; Osawa L; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Kurosaki M; Izumi N
    Cancer Rep (Hoboken); 2022 Nov; 5(11):e1613. PubMed ID: 35302279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.